Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Journey Medical (DERM) EPS (Weighted Average and Diluted) (2020 - 2025)

Journey Medical's EPS (Weighted Average and Diluted) history spans 6 years, with the latest figure at -$0.04 for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) fell 150.0% year-over-year to -$0.04, compared with a TTM value of -$0.47 through Dec 2025, up 36.49%, and an annual FY2025 reading of -$0.47, up 34.72% over the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.04 at Journey Medical, up from -$0.09 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was $0.8 in Q3 2023, with the low at -$1.89 in Q4 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.38, with a median of -$0.18 recorded in 2024.
  • Year-over-year, EPS (Weighted Average and Diluted) plummeted 921.74% in 2021 and then surged 240.35% in 2023.
  • Tracing DERM's EPS (Weighted Average and Diluted) over 5 years: stood at -$1.89 in 2021, then skyrocketed by 68.25% to -$0.6 in 2022, then surged by 80.0% to -$0.12 in 2023, then surged by 166.67% to $0.08 in 2024, then crashed by 150.0% to -$0.04 in 2025.
  • Per Business Quant, the three most recent readings for DERM's EPS (Weighted Average and Diluted) are -$0.04 (Q4 2025), -$0.09 (Q3 2025), and -$0.16 (Q2 2025).